mRNA Lipid Nanoparticles for <i>Ex Vivo</i> Engineering of Immunosuppressive T Cells for Autoimmunity Therapies.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 37906000.
- Also identified by DOI 10.1021/acs.nanolett.3c02573.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Cell-based therapies for autoimmune diseases have gained significant traction, with several approaches centered around the regulatory T (T<sub>reg</sub>) cell─a well-known immunosuppressive cell characterized by its expression of the transcription factor Foxp3. Unfortunately, due to low numbers of T<sub>reg</sub> cells available in circulation, harvesting and culturing T<sub>reg</sub> cells remains a challenge. It has been reported that engineering Foxp3 expression in CD4<sup>+</sup> T cells can result in a T<sub>reg</sub>-like phenotype; however, current methods result in the inefficient engineering of these cells. Here, we develop an ionizable lipid nanoparticle (LNP) platform to effectively deliver Foxp3 mRNA to CD4<sup>+</sup> T cells. We successfully engineer CD4<sup>+</sup> T cells into Foxp3-T (FP3T) cells that transiently exhibit an immunosuppressive phenotype and functionally suppress the proliferation of effector T cells. These results demonstrate the promise of an LNP platform for engineering immunosuppressive T cells with potential applications in autoimmunity therapies.
Medical subject headings
- T-Lymphocytes, Regulatory
- Autoimmune Diseases